Evidence map›Paper›PMID 37707375›Full record

ArticleMolecular cancer research : MCR2023

Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis.

Benjamin L Green, Lauren A Gamble, Laurence P Diggs, Darryl Nousome, Jesse C Patterson, Brian A Joughin, Billel Gasmi, Stephanie C Lux, Sarah G Samaranayake, Markku Miettinen and 4 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03030404 (Hereditary Gastric Cancer Syndromes), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03030404 completednot on this map

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

TypeobservationalSponsorNational Cancer Institute (NCI)Ran2017 to 2025Enrolled733ConditionsStomach Neoplasms, Stomach Cancer, Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS), Hereditary Diffuse Gastric Cancer (HDGC)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Hereditary diffuse gastric cancer: the evolution of a cancer syndrome.Journal of the Royal Society of New Zealand · 2025
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Benjamin L Green *Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-5772-198X
Lauren A Gamble *Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-1389-9196
Laurence P DiggsSurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0009-0001-8470-6670
Darryl NousomeBiomedical Informatics and Data Science, Frederick National Laboratory for Cancer Research, NCI, NIH, Frederick, Maryland.ORCID 0000-0002-5259-8599
Jesse C PattersonKoch Institute for Integrative Cancer Research, MIT Center for Precision Cancer Medicine, Departments of Biology and Bioengineering, Massachusetts Institute of Technology, Cambridge, Maryland.ORCID 0000-0003-1951-7803
Brian A JoughinKoch Institute for Integrative Cancer Research, MIT Center for Precision Cancer Medicine, Departments of Biology and Bioengineering, Massachusetts Institute of Technology, Cambridge, Maryland.ORCID 0000-0003-1022-9450
Billel GasmiSurgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-8061-8278
Stephanie C LuxSurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-3887-1077
Sarah G SamaranayakeSurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-7056-5635
Markku MiettinenLaboratory of Pathology, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-3282-8107
Martha QuezadoLaboratory of Pathology, NCI, NIH, Bethesda, Maryland.ORCID 0009-0004-0941-8662
Jonathan M HernandezSurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0001-7529-0557
Michael B YaffeSurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-9547-3251
Jeremy L DavisSurgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-6334-6936
Center for Cancer Research · USNational Institutes of Health · USFrederick National Laboratory for Cancer Research · US

Funding

Protein Kinase Signaling and Cell Cycle ControlR01ES015339 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 2007 to 2017
$4.3M
Protein Kinase Signaling in the Genotoxic Stress ResponseR35ES028374 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 2017 to 2024
$3.9M
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer TherapiesR01CA226898 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B, HEMANN, MICHAEL · 2019 to 2023
$2.7M
Intramural NIH HHS Z99 CA999999NCI NIH HHS R01 CA226898NIEHS NIH HHS R01 ES015339NIEHS NIH HHS R35 ES028374
6 · The paper itself

Abstract

Stage IA gastric adenocarcinoma, characterized by foci of intramucosal signet ring cells (SRC), is found in nearly all asymptomatic patients with germline pathogenic CDH1 variants and hereditary diffuse gastric cancer syndrome (HDGC). The molecular steps involved in initiating malignant transformation and promoting SRC dormancy in HDGC are unknown. Here, whole-exome bulk RNA sequencing (RNA-seq) of SRCs and adjacent non-SRC epithelium (NEP) was performed on laser-capture microdissected (LCM) regions of interest found in risk-reducing total gastrectomy specimens from patients with HDGC (Clinicaltrials.gov ID: NCT03030404). In total, 20 patients (6 male, 14 female) with confirmed HDGC were identified. Analysis of differentially expressed genes (DEG) demonstrated upregulation of certain individual EMT and proliferation genes. However, no oncogenic pathways were found to be upregulated in SRCs. Rather, SRC regions had significant enrichment in pathways involved in T-cell signaling. CIBERSORTx predicted significant increases in the presence of regulatory T cells (Treg) specific to SRC regions. IHC confirmed an increase in FOXP3+ cells in SRC foci, as well as elevations in CD4+ T cells and HLA-DR staining. In summary, the tumor immune microenvironment is microscopically inseparable from stage IA gastric SRCs using a granular isolation technique. An elevation in CD4+ T cells within SRC regions correlates with clinically observed SRC dormancy, while Treg upregulation represents a potential immune escape mechanism. IMPLICATIONS: Characterization of the tumor-immune microenvironment in HDGC underscores the potential for the immune system to shape the transcriptional profile of the earliest tumors, which suggests immune-directed therapy as a potential cancer interception strategy in diffuse-type gastric cancer.

Indexed as

AdenocarcinomaCarcinoma, Signet Ring CellStomach NeoplasmsAntigens, CDCadherinsCarcinogenesisFemaleGastrectomyGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleTumor MicroenvironmentAntigens, CDCadherinsCDH1 protein, human

Identifiers

PMID37707375
PMCPMC10840796
OpenAlexW4386725941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.